The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02504372




Registration number
NCT02504372
Ethics application status
Date submitted
20/07/2015
Date registered
21/07/2015
Date last updated
19/07/2019

Titles & IDs
Public title
Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
Scientific title
A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS)
Secondary ID [1] 0 0
2015-000575-27
Secondary ID [2] 0 0
3475-091
Universal Trial Number (UTN)
Trial acronym
PEARLS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - pembrolizumab
Other interventions - Placebo

Experimental: Pembrolizumab - Participants receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year (expected maximum 18 doses).

Placebo Comparator: Placebo - Participants receive placebo, IV, every 3 weeks, for one year (expected maximum 18 doses).


Other interventions: pembrolizumab


Other interventions: Placebo


Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Disease-free Survival (DFS)
Timepoint [1] 0 0
Up to 77 months
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Up to 110 months
Secondary outcome [2] 0 0
Lung Cancer Specific Survival (LCSS)
Timepoint [2] 0 0
Up to 110 months

Eligibility
Key inclusion criteria
- Pathological diagnosis of NSCLC confirmed at surgery, any histology. Participants with
two synchronous primary non-small cell lung cancers are excluded from the study

- Union for International Cancer Control (UICC) v7 Stage IB with T = 4 cm, II-IIIA NSCLC
after complete surgical resection with resection margins proved microscopically free
of disease (R0). Carcinoma in situ can be present at the bronchial margin

- Available tumor sample obtained at surgical resection for programmed cell death
ligand-1 (PD-L1) Immunohistochemistry (IHC) expression assessment

- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

- Adequate organ function performed within 10 days of treatment initiation

- Female participants of childbearing potential must have a negative urine or serum
pregnancy test at screening (within 72 hours of first infusion of study medication).
If the urine test cannot be confirmed as negative, a serum pregnancy test will be
required. The serum pregnancy test must be negative for the participant to be eligible

- Female participants of childbearing potential must be willing to use 2 methods of
birth control or be surgically sterile, or abstain from heterosexual activity starting
with the first infusion of study treatment through 120 days after the last infusion of
study treatment

- Female participants who are breast feeding must discontinue nursing prior to the first
infusion of study medication and until 120 days after the last infusion study
treatment

- Male participants must agree to use an adequate method of contraception starting with
the first infusion of study treatment through 120 days after the last infusion of
study treatment

- Absence of severe comorbidities that in the opinion of the Investigator might hamper
the participation to the study and/or the treatment administration

- No prior or planned neo-adjuvant or adjuvant radiotherapy and/or neo-adjuvant
chemotherapy for the current malignancy is allowed
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Evidence of disease at clinical examination and/or baseline radiological assessment as
documented by contrast enhanced chest/upper abdomen CT scan, brain CT/MRI and clinical
examination

- More than 4 cycles of adjuvant therapy

- Prior treatment with anti-programmed cell death (anti-PD)-1, anti-PD ligand-1/2,
anti-CD137, or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) modulators or any
other immune-modulating agents

- Live vaccine within 30 days prior to the first infusion of study treatment

- Current participation or treatment with an investigational agent or use of an
investigational device within 4 weeks of the first infusion of study treatment

- History of Human Immunodeficiency Virus (HIV) (known HIV 1/2 antibodies positive). No
known active Hepatitis B or C

- Chronic use of immunosuppressive agents and/or systemic corticosteroids or any use in
the last 3 days prior to the first infusion of study treatment

- History of interstitial lung disease or (non-infectious) pneumonitis that required
oral or IV steroids (other than COPD exacerbation) or current pneumonitis

- Active autoimmune disease that has required systemic treatment in past 2 years

- History of a hematologic or primary solid tumor malignancy, unless in remission for at
least 5 years with the exception of pT1-2 prostatic cancer Gleason score < 6,
superficial bladder cancer, non melanomatous skin cancer or carcinoma in situ of the
cervix

- Previous allogeneic tissue/solid organ transplant

- Active infection requiring therapy

- Surgery- or chemotherapy-related toxicity (non-hematological) not resolved to Grade 1
with the exception of alopecia, fatigue, neuropathy and lack of appetite /nausea

- Pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the trial, starting with the screening visit through 120 days
after the last infusion of study treatment

- Participant will not be eligible if the participant is or has an immediate family
member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational
site or Sponsor staff directly involved with this trial, unless prospective site
Review Board approval is given allowing exception to this criterion for a specific
participant

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Merck Sharp & Dohme - North Ryde
Recruitment postcode(s) [1] 0 0
- North Ryde
Recruitment outside Australia
Country [1] 0 0
Austria
State/province [1] 0 0
Vienna
Country [2] 0 0
Belgium
State/province [2] 0 0
Brussels
Country [3] 0 0
Brazil
State/province [3] 0 0
Sao Paulo
Country [4] 0 0
Canada
State/province [4] 0 0
Quebec
Country [5] 0 0
Chile
State/province [5] 0 0
Santiago
Country [6] 0 0
Czechia
State/province [6] 0 0
Prague
Country [7] 0 0
Denmark
State/province [7] 0 0
Glostrup
Country [8] 0 0
Estonia
State/province [8] 0 0
Tallinn
Country [9] 0 0
France
State/province [9] 0 0
Paris
Country [10] 0 0
Germany
State/province [10] 0 0
Haar
Country [11] 0 0
Greece
State/province [11] 0 0
Alimos
Country [12] 0 0
Hungary
State/province [12] 0 0
Budapest
Country [13] 0 0
Ireland
State/province [13] 0 0
Dublin
Country [14] 0 0
Israel
State/province [14] 0 0
Hod Hasharon
Country [15] 0 0
Italy
State/province [15] 0 0
Rome
Country [16] 0 0
Japan
State/province [16] 0 0
Chiyoda-Ku, Tokyo
Country [17] 0 0
Korea, Republic of
State/province [17] 0 0
Seoul
Country [18] 0 0
Latvia
State/province [18] 0 0
Riga
Country [19] 0 0
Netherlands
State/province [19] 0 0
Haarlem
Country [20] 0 0
Peru
State/province [20] 0 0
Lima
Country [21] 0 0
Poland
State/province [21] 0 0
Warsaw
Country [22] 0 0
Portugal
State/province [22] 0 0
Paco Darcos
Country [23] 0 0
Russian Federation
State/province [23] 0 0
Moscow
Country [24] 0 0
Slovenia
State/province [24] 0 0
Ljubljana
Country [25] 0 0
Spain
State/province [25] 0 0
Madrid
Country [26] 0 0
Switzerland
State/province [26] 0 0
Lucerne 6
Country [27] 0 0
Turkey
State/province [27] 0 0
Istanbul
Country [28] 0 0
United Kingdom
State/province [28] 0 0
Hoddesdon

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Merck Sharp & Dohme Corp.
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
ETOP
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
European Organisation for Research and Treatment of Cancer - EORTC
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
In this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who have
undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant
chemotherapy will be treated with pembrolizumab or placebo. The primary study hypothesis is
that pembrolizumab will provide improved disease-free survival (DFS) versus placebo.
Trial website
https://clinicaltrials.gov/show/NCT02504372
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Merck Sharp & Dohme Corp.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Toll Free Number
Address 0 0
Country 0 0
Phone 0 0
1-888-577-8839
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT02504372